Total
0
Shares
XPhyto: Innovating a Therapeutic Psychedelic Drug Pipeline
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness (PSYC) and its clinical research partner have commenced the next preclinical trial with AME-1
  • AME-1 is the company's proprietary extract from Amanita mushrooms
  • This toxicity study of AME-1 will determine the dose(s) that will be administered for a subsequent long-term 90-day toxicity study
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products
  • Psyched Wellness (PSYC) opened trading at C$0.31 per share

Psyched Wellness (PSYC) and its clinical research partner KGK Science have commenced the next preclinical trial study with AME-1.

This new 14-day oral toxicity study of AME-1 will determine the dose(s) that will be administered for a subsequent long-term 90-day oral toxicity study.

The goal of this study is to determine dose-dependent effects along with determining the highest dose that is safe to use for a longer-term study. This is another key milestone in the further understanding of the effects of Psyched Wellness' AME-1 extract under a scientific methodology in pursuit of a safe dose for human consumption.

"This represents another milestone event in the scientific study of AME-1. The results of this study will further increase the knowledge and further identify the physical and chemical properties of AME-1," says Brian Tancowny, scientific advisor for Psyched Wellness.

"The pre-clinical trial we are currently conducting is part of a number of smaller studies that need to happen in a specific order and, when completed, will combine to provide the foundation off of which our future products will be developed.

As we embark on a new study or complete a study, we add significant value to the company as we are pioneering a path to market for AME-1 derived health and wellness products," says Jeff Stevens, CEO of Psyched Wellness.

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched Wellness (PSYC) opened trading at C$0.31 per share.

More From The Market Herald
Clearmind Medicine (CSE:CMND) announces closing of private placement

" Clearmind Medicine (CSE:CMND) partners with The Hebrew University

Clearmind Medicine (CMND) has established a research and development partnership with the Yissum Research Development Company.
Small Pharma - CEO, Peter Rands (third from left) and the Small Pharma team. - The Market Herald Canada

" Negev Capital doubles down on Small Pharma (TSXV:DMT)

Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT).
PharmaTher (CSE:PHRM) added to the North American Psychedelics Index & the Horizons Psychedelic Stock Index ETF

" PharmaTher (CSE:PHRM) added to the North American Psychedelics Index & the Horizons Psychedelic Stock Index ETF

PharmaTher Holdings (PHRM) has been included in the North American Psychedelics Index.
Silo Wellness (CSE:SILO) debuts Marley One in collaboration with the Bob Marley family

" Psyched Wellness (CSE:PSYC) initiates a clinical sleep study

Psyched Wellness (PSYC) has initiated a clinical study of its AME-1 as a sleep-enhancing food supplement for self-declared insomniacs.